Method of quantifying lysergic acid diethylamide (LSD) and 2,3-dihydro-3-hydroxy-2-oxo lysergide (O-H-LSD) in human plasma
A method of measuring and identifying LSD and its major metabolite O-H-LSD, by obtaining a sample from an individual, and measuring, identifying, and quantifying LSD and O-H-LSD in the sample by performing a LC-MS/MS analysis. A method of treating and monitoring individuals taking LSD, by administering a microdose of LSD, a prodrug of LSD, or an analog of LSD to the individual, monitoring the individual by obtaining a sample from an individual and measuring and identifying the analytes in the sample by performing a LC-MS/MS analysis, and adjusting the microdose based on the amount of LSD quantified in the LC-MS/MS analysis. A method of adjusting dosing of LSD, by administering a microdose of LSD, a prodrug of LSD, or an analog of LSD to the individual, and adjusting the microdose based on blood concentration analytics.
1. A method of treating and monitoring an individual taking LSD, including the steps of:
administering a microdose of LSD, a prodrug of LSD, or an analog of LSD to the individual;
monitoring the individual by obtaining a sample from an individual of about 300 μL of plasma and measuring and identifying analytes in the sample by performing a LC-MS/MS analysis by aliquoting about 50 μL of the sample and mixing with internal standard working solution of acetonitrile, precipitating plasma proteins in the sample with acetonitrile, centrifuging the aliquot, injecting the aliquot into an LC-MS/MS system, diluting the injected aliquot online via a T-union installed in front of a pH resistant analytical column, and detecting LSD and O-H-LSD by multiple reaction monitoring in positive and negative electrospray ionization, wherein analysis of the sample can be run in about 4 minutes, and wherein analysis can quantify 0.5 pg LSD; and
adjusting the microdose based on the amount of LSD measured and identified in the LC-MS/MS analysis.
2. The method of claim 1 , wherein the individual is not responding to the microdose.
3. The method of claim 1 , further including the step of identifying if the individual is a slow or rapid metabolizer.
4. The method of claim 1 , further including the step of diagnosing an intoxication.
5. The method of claim 1 , wherein the microdose is 5 to 200 μg.